NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines

Phase 1

Completed

Conditions: Prostatic Cancer
Prostatic Neoplasms

Interventions: Biological: ETBX-071; adenoviral PSA vaccine
Biological: ETBX-061; adenoviral MUC1 vaccine
Biological: ETBX-051; adenoviral brachyury vaccine

First Posted Date: 2018-03-29

Last Posted Date: 2021-05-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT03481816

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer

Phase 1

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Enzalutamide Liquid
Drug: Enzalutamide Capsule

First Posted Date: 2018-03-27

Last Posted Date: 2021-05-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1

Registration Number: NCT03478904

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Stage IV Lung Non-Small Cell Cancer AJCC v7

Interventions: Biological: Nivolumab
Drug: Cabozantinib
Biological: Ipilimumab

First Posted Date: 2018-03-19

Last Posted Date: 2023-10-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3

Registration Number: NCT03468985

Locations: 🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸
Grant Medical Center, Columbus, Ohio, United States
🇺🇸
The Mark H Zangmeister Center, Columbus, Ohio, United States

and more 465 locations

Losartan for the Treatment of Pediatric NAFLD

Phase 2

Terminated

Conditions: NAFLD - Nonalcoholic Fatty Liver Disease

Interventions: Drug: Losartan potassium
Drug: Placebo losartan capsule

First Posted Date: 2018-03-15

Last Posted Date: 2021-10-21

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 83

Registration Number: NCT03467217

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Northwestern Univ-Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸
University of Washington, Seattle, Washington, United States

and more 7 locations

M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas

Phase 1

Terminated

Conditions: Pancreatic Adenocarcinoma
Pancreatic Neoplasms
Pancreas Cancer
Cancer of Pancreas
Pancreatic Cancer

Interventions: Drug: M7824
Drug: Gemcitabine

First Posted Date: 2018-03-02

Last Posted Date: 2021-06-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 7

Registration Number: NCT03451773

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Phase 1

Completed

Conditions: B-Cell Lymphoma
Acute Lymphocytic Leukemia
B-Cell Leukemia
B-Non Hodgkin Lymphoma
Lymphoma, Non-Hodgkin
Leukemia, Lymphocytic, B Cell
Acute Lymphoid Leukemia
B-NHL
Acute Lymphoblastic Leukemia
B-All

Interventions: Biological: CD19/CD22 CAR T-Cells
Drug: Fludarabine
Drug: Cyclophosphamide
Procedure: Apheresis
Other: Anti-emetic
Drug: Diphenhydramine
Drug: Acetaminophen
Diagnostic Test: ECG
Diagnostic Test: ECHO
Diagnostic Test: MRI Brain
Procedure: Bone marrow biopsy
Diagnostic Test: Cardiac MRI

First Posted Date: 2018-02-28

Last Posted Date: 2025-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 54

Registration Number: NCT03448393

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma

Phase 1

Terminated

Conditions: Mesothelioma

Interventions: Drug: LMB-100
Drug: SEL-110

First Posted Date: 2018-02-19

Last Posted Date: 2019-11-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 5

Registration Number: NCT03436732

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females

Phase 1

Completed

Conditions: Prostatic Neoplasms

Interventions: Drug: Zolpidem
Diagnostic Test: ECG

First Posted Date: 2018-02-19

Last Posted Date: 2025-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT03436745

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Biospecimen Procurement for Head and Neck Disorders

Recruiting

Conditions: Hearing Disorder
Head and Neck Neoplasms
Oral Mucosal Disease
Pharyngeal Neoplasm
Laryngeal Disease

First Posted Date: 2018-02-12

Last Posted Date: 2025-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1000

Registration Number: NCT03429036

Locations: 🇺🇸
George Washington University Hospital, Washington, District of Columbia, United States
🇺🇸
Johns Hopkins Hospital Bayview, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins Hospital Sibley Memorial Hospital, Washington, District of Columbia, United States

and more 6 locations

Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus

Phase 2

Terminated

Conditions: Type1 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Hydroxychloroquine

First Posted Date: 2018-02-12

Last Posted Date: 2024-04-09

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 273

Registration Number: NCT03428945

Locations: 🇸🇪
Skane University Hospital, Malmö, Sweden
🇺🇸
Joslin Center at SUNY Upstate Medical University, Syracuse, New York, United States
🇺🇸
Endocrinology Specialist / Greenville Health System, Greenville, South Carolina, United States

and more 48 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy